Mind-Da le
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1336502749
Payments from drug & device makers
Across 230 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$646
- Boehringer Ingelheim$516
- Radius Health, Inc.$347
- Xeris Pharmaceuticals, Inc.$339
- Corcept Therapeutics$328
- Dexcom, Inc.$299
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,220100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 27 | $646 |
| Boehringer Ingelheim | 18 | $516 |
| Radius Health, Inc. | 15 | $347 |
| Xeris Pharmaceuticals, Inc. | 18 | $339 |
| Corcept Therapeutics | 16 | $328 |
| Dexcom, Inc. | 15 | $299 |
| Sanofi-aventis U.S. LLC | 9 | $252 |
| Amgen | 10 | $196 |
| Antares Pharma, Inc. | 12 | $194 |
| Neurocrine Biosciences, Inc. | 5 | $155 |
| Tandem Diabetes Care, Inc. | 5 | $147 |
| Novo Nordisk | 8 | $147 |
| BETA Bionics, Inc. | 3 | $147 |
| Averitas Pharma Inc. | 5 | $139 |
| Abbott | 6 | $131 |
| Ascendis Pharma Endocrinology Inc | 5 | $130 |
| Bayer | 1 | $125 |
| Amneal Pharmaceuticals LLC | 6 | $119 |
| Kyowa Kirin, Inc. | 6 | $108 |
| IBSA Pharma Inc. | 6 | $102 |
| Pfizer | 5 | $98 |
| Mannkind Corporation | 5 | $91 |
| Avvisto Therapeutics, LLC | 4 | $59 |
| Madrigal Pharmaceuticals | 2 | $50 |
| Medtronic | 2 | $48 |
| Halozyme Inc | 3 | $45 |
| AbbVie | 3 | $44 |
| Sequel Med Tech, LLC | 1 | $39 |
| Insulet Corporation | 2 | $37 |
| Soleno Therapeutics, Inc. | 1 | $30 |
| Rhythm Pharmaceuticals, Inc. | 1 | $25 |
| Embecta Corp. | 1 | $21 |
| Alvogen Inc | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Tolmar, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,224 in reported general payments places this provider in the 50th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 119 | $215,121 |
| MounjaroTirzepatide | 62 | $117,889 |
| JardianceEmpagliflozin | 45 | $56,152 |
| ForteoTeriparatide | 11 | $54,833 |
| RybelsusSemaglutide | 27 | $41,533 |
| FarxigaDapagliflozin Propanediol | 16 | $22,949 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $21,625 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $21,084 |
| TrulicityDulaglutide | 16 | $19,436 |
| TradjentaLinagliptin | 19 | $17,181 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $16,661 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $10,613 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $6,364 |
| Humalog Kwikpen U-100Insulin Lispro | 25 | $5,231 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 32 | $3,971 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $147 | $256,655146 claims |
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $646 | $192,15889 claims |
| Boehringer IngelheimJardiance, Tradjenta | $516 | $73,33364 claims |
| AstraZenecaFarxiga | $19 | $22,94916 claims |
| AbbVieSynthroid | $44 | $3,29942 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $119 | $2,264115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Dallas
- Julio RosenstockDallas$24.9M
- Ildiko LingvayDallas$8.2M
- Peter BresslerDallas$4.2M
- Steve FordanDallas$2.8M
- Pablo MoraDallas$2.1M
- Saleemah FahmiDallas$1.2M
- Priscilla HollanderDallas$1M
- Oksana HamidiDallas$1M
- Amy ShahDallas$953K
- Abhimanyu GargDallas$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.